Document Detail


Involvement and therapeutic potential of the GABAergic system in the fragile X syndrome.
MedLine Citation:
PMID:  21057732     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
Many drugs have been developed that are able to modulate the GABAergic system, which is involved in anxiety, depression, epilepsy, insomnia, and learning and memory. The recent observation that the GABA(A) receptor is underexpressed in the fragile X syndrome, an inherited mental retardation disorder, therefore raised hopes for targeted therapy of the disorder. This review summarizes the lines of evidence that demonstrate a malfunction of the GABAergic system. The GABAergic system clearly emerges as an attractive target for therapy of the fragile X syndrome, and thus provides an excellent example of how genetic research can lead to unique opportunities for treatment.
Authors:
Inge Heulens; Charlotte D'Hulst; Sien Braat; Liesbeth Rooms; R Frank Kooy
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-04
Journal Detail:
Title:  TheScientificWorldJournal     Volume:  10     ISSN:  1537-744X     ISO Abbreviation:  ScientificWorldJournal     Publication Date:  2010  
Date Detail:
Created Date:  2010-11-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101131163     Medline TA:  ScientificWorldJournal     Country:  England    
Other Details:
Languages:  eng     Pagination:  2198-206     Citation Subset:  IM    
Affiliation:
Department of Medical Genetics, University of Antwerp, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The nuclear hormone receptor PPAR? as a therapeutic target in major diseases.
Next Document:  Time-space translation: a developmental principle.